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Abstract: The elderly population is projected to make up 20% of the total United States popu-
lation by the year 2030. In addition, epidemiological data suggests increasing prevalence of 
chronic pain and frailty with advancing age. Pain, being a subjective symptom, is challenging to 
manage effectively. This is more so in elderly populations with age-specific physiological changes 
that affect drug action and metabolism. Elderly patients are also more likely to have multiple 
chronic health pathologies, declining function, and frailty. The barriers present for patients, 
providers, and health systems also negatively impact efficient and effective pain control. These 
factors result in disproportionate utilization of health resources by the older population group. 
The scientific literature is lagging behind in age-specific studies for the elderly population. As 
a result, there is a lack of age-specific standardized management guidelines for various health 
problems, including chronic pain. Increasing efforts are now being directed to studies on pain 
control in the elderly. However, pain management remains inconsistent and suboptimal. This 
article is an attempt to suggest an informed, comprehensive guide to achieve effective pain 
control in the presence of these limitations.
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Introduction
Advancements in the field of medicine over the last century have resulted in a significant 
increase in mean survival age1 and have changed the age distribution curve by adding 
older adults in the canvas of global population. While investigators must continue 
finding solutions to medical problems of younger populations, the increasingly aging 
population brings a different set of puzzles to medicine. We are testing the limits of 
the health care system with additional physical, social, and economical stress.
Epidemiology of old age
Aging is a normal physiological process characterized by a dynamic, irreversible 
decline in physiological function.2 Old age (or the older adult) is defined as the age of 
65 or older, and the last century had seen escalation in the aging population. This older 
age population has risen from 4% of the total population in 1900 to 13% in 2010. The 
trend suggests that the older age population will expand to reach 20%–21% of total 
population by the year 2030.3 Continuous advancements in medicine, and improved 
hygiene and nutrition are tempering some of the rise of chronic disability in the elderly 
ie, 81% older adults identified themselves as nondisabled in 2005 in comparison with 
73% in 1982.4
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Frailty
Altered physiology and increases in degenerative disease 
prevalence have influence on the health status of older adults. 
In one estimate 30%–50% of adults 65 years and older have 
two or more health problems affecting their life. For those 
85 years and over, this statistic rises to 50%–75%.
The interaction of various medical pathologies with 
age-related body changes results in a physiologic change 
characterized by decreased ability to respond to stressors. 
It causes vulnerability to adverse health outcomes, such 
as functional impairment, falls, fractures, social isolation, 
hospitalization, etc. This vulnerability is defined as frailty.5 
Frailty is diagnosed upon presence of three out of these five 
factors: (a) weight loss, (b) extreme fatigue, (c) weakness 
in hand grip, (d) slow walking speed, and (e) low physical 
activity in older adults.5 Altered cognition, depression, and 
loss of muscle mass is very common in a frail patient. Pain 
remains the most common complaint in this group.
Geriatric pain
Along with increasing chronic degenerative changes and 
multiple medical comorbidities, the prevalence of pain also 
increases with advancing age. It ranges from 50%–75% 
and remains underdiagnosed and undertreated.6 Poorly con-
trolled pain, in turn, causes impaired activities of daily liv-
ing (ADLs), mood disturbances, decreased ambulation, and 
cognitive alteration. Collectively, these comorbidities lead 
to other medical morbidities, such as deep vein thrombosis 
(DVT), pulmonary embolism, fractures, and poor quality of 
life.7 Thus, it is of utmost priority to diagnose and manage 
pain early and effectively.
Pain cure is still an elusive target. The lack of optimal guide-
lines and inconsistent management make pain even more dif-
ficult to manage. Thus, the International Association of Study 
for Pain (IASP) accepted the declaration “Pain management – a 
fundamental human right” at Montreal in 2010.8
Pain is an unpleasant, subjective, multifaceted, biopsycho-
social experience.9 It encompasses sensory- discriminative, 
affective-motivational, and cognitive- interpretive  dimensions. 
Each of these components is influenced by physical, psycho-
logical, social, and spiritual factors.10 To achieve effective 
pain control, all of these factors should be addressed.
Challenges in geriatric pain 
management
There are several factors that make delivery of effective 
pain management in geriatric population a challenging task. 
In order to provide effective pain management, we should 
understand the pathophysiology of pain and the barriers to 
delivery of appropriate pain care.
Pain process
The pain process11 is comprised of four stages: 
(1) Nociception – stimulation of the peripheral pain receptors; 
(2) Pain Transmission – travelling of pain signals through 
C- and A-delta fibers from the periphery to the dorsal horn 
and ascending in the spinal tracts to the central level; (3) Pain 
Modulation – modulation of pain signals along the neuraxial 
pain pathway; and (4) Pain Perception – projection of the 
pain signal onto the somatosensory cortex.
There are various receptors and neurotransmitters along this 
pathway that help in translating this action potential from the 
nociceptors at the periphery into pain perception.  Alterations 
at these stages are the targets for pain management.
Physiologic alterations in older adults
With advancing age, multiple physiological changes occur in 
the body, altering the pharmacodynamics and pharmacokinetics 
of drugs. This in turn complicates pain  management. Changes 
that occur with aging are summarized in Table 1.12,13
Barriers in geriatric pain management
Beside the physiological and pathological changes, there are 
several other factors that hinder optimal pain care delivery.14,15 
The shareholders invested in the goal of pain relief also bring 
their individual prejudices and limitations:
a. Patient themselves through
• Misconceptions (increasing disease, pain as part of 
aging, nontreatable, medicines should be a last resort),
• Fear (of addiction, masking disease progression, being 
labeled as a weak or bad patient, adverse effects from 
drugs, loss of independence),
• Personality (noncompliance, not wanting to be 
“a complainer,” denial, negative attitude towards 
younger practitioners),
• Personal (cultural and religious beliefs, language, mon-
etary status, comfort with health care setting, ambula-
tory status, social support),
• Comorbidities (depression, dementia, altered cognition, 
etc);
b. Medical professionals through
• Lack of knowledge/training (for pain diagnosis, assess-
ment, nonpharmacologic modalities, medication’s 
side effects and dependence or addiction) resulting in 
inability to diagnose early, manage effectively, interpret 
symptoms and side effects, and delay in referral,
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• Lack of standardized guidelines and protocols for pain 
management,
• Personal biases (towards fear of opioid dependence, addic-
tion, opioid toxicity, legal scrutiny, patient satisfaction),
• Time constraints;
c. Health system through
• Accessibility (distance, transportation, insurance 
 coverage, economics, social support, etc),
• Facility and health care deficiencies (clear guidelines 
and protocols, trained professionals, insufficient sup-
portive and ancillary staff, insufficient resources, exces-




• Medicine (availability, polypharmacy, complex dos-
age regimen, adverse effects, generic vs brand name 
medications, packaging),
• Off-label usage of medications or interventions.
Adverse effects and compliance in elders
An undesired and potentially harmful response from medica-
tions is more prevalent in the older adult population. In sev-
eral studies, the incidence of these adverse reactions ranges 
from 6% to 30%, and the majority of them are preventable.16 
Polypharmacy, multiple prescribers, inappropriate use, sub-
optimal monitoring, and patient compliance are risk factors 
for adverse events. This is in addition to variances seen 
secondary to age-related pharmacodynamic and pharma-
cokinetic changes of drug metabolism.17
Adverse reactions should not be confused with thera-
peutic failure, which is described as “given medication but 
unable to achieve goal of therapy.” A combination of any 
of the following factors may be responsible for therapeutic 
failure: poor adherence to medicine, inadequate dosing, drug 
interactions, and unaffordable cost of medications.18
In the presence of multiple health problems, the elderly 
population is often at risk for polypharmacy.19 Prior to 
instituting a new medication, a clear goal, end point, rate 
of taper and duration, appropriate monitoring, possible 
side effects, and drugs interactions should be considered to 
prevent these adverse events. Ongoing efforts are directed 
at the development of screening tools and lists of high-risk 
medications to help health care providers choose safe and 
effective medications for older adults.
A list of medications that pose potential risks outweighing 
potential benefits for the older population was suggested in 
1991, called the “Beers Criteria for Potentially Inappropri-
ate Medication Use in Older Adults.”20 The list was recently 
updated and modified into three broad categories of high-risk 
Table 1 Physiologic changes with aging and its effects









Liver Small liver mass
Reduced hepatic blood flow
Decreased hepatic enzymes








Cardiac Decreased cardiac index Rapid and high drug peak Higher toxicity risk
Renal Reduced size
Decreased renal blood flow
Reduced renal function (gfr),  
1% per year after age 50
Decreased renal elimination Required dose adjustment
General Increased body fat
Decreased body water
Increased volume of distribution  
for lipophilic medication
Increased plasma concentration  
of hydrophilic drugs
Delayed elimination and onset  
of drug of action
Higher frequency of side effects
Nervous system Decreased cerebral blood flow
Neuronal loss/atrophy
Decreased synthesis of neurotransmitters
Decreased opioid receptor density
Decreased descending inhibitory  
pain control and altered  
pain processing
Increased pain with noxious stimuli
Altered response to pain
Muscle Decreased muscle mass Decreased functioning
Abbreviation: gfr, glomerular filtration rate.
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medications for elders (a) in general, (b) in certain specific 
diseases, or (c) to be used with caution. Concomitant use of 
the Beers criteria and the “screening tool for older persons 
prescriptions (STOPP)/screening tool to alert to right treat-
ment (START)” criteria21 helps health care providers to 
deliver safe and effective medicinal management.
Management of geriatric pain
“Access to pain management is a fundamental right,”8 and 
 accurate assessment and delivery of effective treatment in 
timely fashion are critical for better outcomes and patient 
 satisfaction. Understanding the complexities associated 
with pain  management should further challenge medical 
 practitioners. They must put in diligent effort to provide effective 
pain control through optimal use of knowledge and tools.
Pain assessment
Pain assessment is the key to optimal pain control and deter-
mination of its mechanism in elderly populations.
Patient’s self-reporting is the most reliable source in pain 
assessment.22 Comprehensive pain assessment is an ongoing 
process in elderly patients, and information may be gained by 
comparing repeated interactions with health care workers.
A medical history inclusive of pain symptoms detailing 
location, duration, character, radiation, temporal relation-
ships, and associated neural symptoms helps to narrow down 
the differential diagnosis. History of medication use and 
effects is also an essential part of the assessment.
This is further aided by a physical examination, with focus 
on the patient’s complaints. The patient’s cognitive capacity 
may be diminished by other comorbidities. Thus, a thorough 
physical examination and history is essential. Relevant diag-
nostic tests further compliment the clinical assessment.
Although pain is a subjective symptom, its accurate 
measurement helps to compare and improve the outcomes 
of management modalities. Choices of pain measurement 
tools are dependent upon the patient’s cognitive, visual, 
 auditory, and communicative status. Pain can be rated using: 
(a) unidimensional scales – these include numeric pain rating 
scales and pictorial pain rating scales (ie, faces pain scale, 
colored visual analogue scale, pain thermometer, etc) and are 
commonly used to rate the intensity of pain; or (b) multidi-
mensional verbal descriptor scales, such as the McGill Pain 
Questionnaire23 (describes sensory and emotional effect of 
pain), the Multidimensional Pain Inventory, etc.24
Pain assessment is not complete without evaluating the 
impact of the pain on the patient. Pain affects the patient’s 
psychological and functional status and its impacts may 
also extend to affect cultural, spiritual and social function 
of the family and community. It is critical to understand 
these impacts to provide multidisciplinary pain management. 
Patient’s mood, coping skills, ability to perform ADLs, use 
of aids, social and family interactions, etc must be evaluated 
before formulating the management plan.
Pain assessment is especially challenging in patients with 
cognitive impairment and dementia, placing this group at risk 
of under diagnosis and undertreatment.25 When self-report 
is unavailable, as in the cognitively impaired person, obser-
vation of the patient’s behavior pattern will be the primary 
assessment tool.
Attempts have been made to develop common instruments 
or guidelines for assessing pain in communicatively and cog-
nitively impaired patients. A hierarchical Pain Assessment 
Algorithm26 was proposed that can be utilized for patients who 
are self-reporting as well as for cognitively impaired patients. 
It consists of (a) a self-report from patient (or reason for not 
doing it); (b) behavioral assessment tools for observation of pain 
behaviors during clinical assessment; (c) an assessment report 
by the patient’s caregivers; and (d) a listing of analgesic trials 
and nonpharmacologic interventions and their outcomes.
Management of pain
Managing pain is a challenging task to begin with and it is 
especially difficult in the elderly population, secondary  chal-
lenges in their pain assessment. With the lack of age- specific 
scientific evidence, it is often common to extrapolate the 
data from young adult studies for clinical decision-making 
in elders. There is an increased risk of medicine-associated 
adverse events from polypharmacy, lack of age-appropriate 
treatment guidelines and protocols, lack of age-appropriate 
drug safety data, multiple comorbidities, and age-related 
physiological changes. On the other end, aging is also a 
very individualized process, and age-related changes are 
extremely varied among individuals.
It is important to keep all these challenges, diagno-
ses, resources, and patient expectations in perspective, to 
formulate comprehensive multidisciplinary management 
strategies (Figure 1). Pain is a multifaceted problem and 
is best addressed through an individualized approach. The 
goal should be not only to improve pain control, but also, to 
improve function and alter pain behaviors.
Education
Educating both the patients and their health care providers 
can overcome the prominent barriers to the implementation 
and delivery of effective pain management.
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Nonpharmacological modalities
Nonpharmacological modalities27 is essential component for 
comprehensive multimodal management strategies as it helps 
patient in coping better with pain and suffering along with 
improvement in daily functions. Thus these modalities includ-
ing physical therapy, psychobehavioral therapies,28 pastoral 
and social work consultation should not be overlooked.
In the frail elderly, it is even more important to improve 
function, as one of the key modalities in the prevention and 
management of frailty. Adequate analgesia enables the patient 
to participate fully and progress in a tailored exercise program, 
preferably one provided by a physical therapy specialist.
Identification of patients who are at high-risk for fall 
and fractures is essential. Ergonomic adjustment in patient’s 
lifestyle can be made to prevent falls or bad outcome from 
falls. Examples of adjustments include clearing obstacles 
from passages, softer padding along the passages, and use 
of walking aid.
A nutritional consultation could be very beneficial for 
better nutrition, to prevent loss of muscle mass, osteoporosis, 
and better control of chronic conditions.
Pharmacological modalities
The multidimensional character of pain makes it more dif-
ficult for researchers to develop clear, standard protocols for 
pain management. Geriatric pain thus can be best managed 
using individualistic and mechanistic treatment strategies.
Pain is classified into broad categories as: nociceptive, 
neuropathic, psychosocial, visceral, and mixed. Analgesics 
such as opioids, acetaminophen, and nonsteroidal anti-
inflammatory drugs are known to be more effective for 
nociceptive pain. Meanwhile, adjuvants medications, includ-
ing antiepileptics and antidepressants, are more helpful in 
neuropathic pain. One should determine the particular type 
of pain prior to prescribing first-line medications.
Several of these pharmacological agents have multiple 
delivery routes ie, oral, intravascular, sublingual, mucosal, 
rectal, transdermal, and intramuscular. Selection of the least 
invasive route of drug delivery should be the priority in 
elderly patients.
Upon selection of the medication, this should be started 
in the lowest effective dose, followed by a gradual and slow 
titration of dosage.29 There should be adequate intervals 
between the escalations of medication during titration, to 
prevent overdosage and side effects from accumulative 
doses. Although these intervals are not clearly defined in the 
literature, titration schedules should consider the expected 
half-life of the medication; in general it takes five times the 
elimination half-life to reach steady state.30 Titration may also 
be influenced by a patient’s response to medication use. All 
along this therapeutic trial, the patient should receive medica-
tions around the clock, be closely monitored for therapeutic 
effect, and report any adverse effect or intolerability. Since 
mixed pain can often occur, the addition of medications 
with different mechanisms should not be delayed. Providers 
should be very careful about drug–drug or drug–disease 
interactions.
The WHO three-step “analgesic ladder”31 was initially 
recommended for the management of cancer pain, with 
emphasis on oral opioids as per the intensity of pain. In time, 
its use has expanded for managing noncancer pain, includ-
ing pain in the geriatric population. The goal remains the 
slow escalation of analgesic dosing to achieve the desired 
therapeutic goal. Adjuvant medications should be used at the 
same time, to achieve better analgesia and reduce the opioid 
consumption. Use of the analgesic ladder has been validated 
through various studies and achieves the goal of pain relief 
in 70% of cases,31 but its use is limited to communicative 
patients who can take oral medications.
Attention should be given to the patient’s physiologi-
cal, cognitive, and comorbid status. Avoid usage of strong 
opioids, nonsteroidal anti-inflammatory agents, and tricyclic 
antidepressants in the elderly patient.29
Pain medications can be classified according to three 
broad categories: nonopioid analgesics, opioid analgesics, 
and adjuvant medications.
Nonopioid analgesics
Acetaminophen, nonsteroidal anti-inflammatory drugs 
(NSAIDs), and steroids are the most commonly used nonopi-
oid analgesics. Acetaminophen is a centrally acting analgesic 
without anti-inflammatory properties. It is metabolized by 
liver and excreted through the renal system. It is used as an 
analgesic and also as coanalgesic, meaning it potentiates 
the effect of opioid analgesics and provides opioid sparing. 
Acetaminophen is an initial analgesic used for mild pain and 
for ongoing persistent pain. Caution should be exercised in 
liver or renal impairment, when doses should be adjusted. 
Dose escalation is limited, secondary to a ceiling of its effect 
on analgesia. Dosages should be limited to 2000 mg per day 
in the elderly.
Chronic usage of NSAIDS should be avoided in the 
elderly population as these carry a high risk for gastrointes-
tinal toxic effects, and renal and cardiac dysfunction. Short-
term use is suggested, upon cautious assessment of patient 
comorbidities and with close monitoring for gastrointestinal 
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and renal adverse effects as well as for drug to drug interac-
tions. Concomitant use of a gastro-protective agent (ie, proton 
pump inhibitor) is recommended with NSAIDs use.29 Topical 
NSAIDs may be a safe alternate, secondary to their reduced 
systemic absorption.32
Opioid analgesics
Opioid analgesics are commonly used for moderate to severe 
pain and pain associated with frailty. They provide analge-
sia through action on opioid receptors that are present both 
peripherally as well as in the central nervous system. The 
WHO analgesic ladder31 guides in the selection and dosing of 
opioids for moderate pain and severe pain; thus, they are clini-
cally divided in to mild and strong opioids. Hydrocodone, 
tramadol, and oxycodone are considered mild opioids and 
can be used for moderate pain that is not controlled by use 
of nonopioid analgesics. Upon failure to achieve appropriate 
analgesia with mild opioids, stronger opioids, such as mor-
phine, oxycodone, oxymorphone, hydromorphone, fentanyl, 
and methadone, should be used. Most of the strong opioids 
are available in fast-acting and long-acting formulation. In 
the case of fast-acting opioids, the formulation half-life is 
usually 2–6 hours, based upon metabolism of the drug. The 
long-acting formulations allow 8–12 hours of analgesia 
through sustained-release drug delivery systems ie, matrix-
based slow-release MS Contin® or reservoir-based fentanyl 
patches. The exception is methadone, which is limited by its 
pharmacodynamic profile.33
Patients should be reassessed frequently with every 
change in dosing, to monitor its efficacy and side effects.29 
In order to prevent side effects from progressing to a 
poor  outcome, it is essential that the provider manage 
 preemptively. Depending upon the patient’s health status 
and severity of pain, a fast-acting opioid formulation should 
be started at the lowest effective dose and allowed to titrate 
slowly. Titration of the dose should be done by increasing 
each dose by 30%–50% of the current total daily dose33 at a 
minimum interval of every 24 hours until stabilization at the 
dose of effective analgesia.34 For severe pain, more frequent 
titration is recommended. It may be appropriate to initiate 
use of a long-acting opioid formulation after monitoring the 
usage of a short-acting opioid formulation. The metabolism 
of hydromorphone, oxycodone, and methadone is directly 
dependent on liver function, while elimination of morphine 
depends upon renal function. Thus, fentanyl could be a 
preferential opioid in liver dysfunction,35 while methadone 
and fentanyl are the agents of preference for patients with 
impaired renal function.36 Morphine, hydromorphone, and 
hydrocodone should be used with caution in hepatic and 
renal impairment; methadone use is commonly avoided 
in these situations, secondary to its complex and variable 
metabolism.35,36
Propoxyphene, meperidine, pentazocine, and high-dose 
tramadol (.200 mg/day) should be avoided in elderly 
patients, secondary to the risk that accumulation of their 
metabolites could lead to undesired side effects.29 Early in 
a patient’s management, long-acting opioid formulations 
should be avoided, secondary to their altered metabolism, 
presence of polypharmacy, and increased risk of side effects. 
For chronic pain management, long-acting formulations may 
be reasonable choices, while fast-acting formulations are 
utilized for breakthrough and incidental pain.
Methadone is a complex medication in comparison with 
the other opioids. Although it may be cost effective, there are 
unpredictable differences in its drug action and clearance. 
Classically understood, methadone is characterized by an 
analgesic half-life of 3–6 hours, while the elimination half-
life may range from 20 hours to in excess of 120 hours. This 
creates real challenges for practitioners when titrating the 
medication on an outpatient basis. Thus, the use of metha-
done requires a physician with experience and understanding 
of the medication, along with the need for frequent monitor-
ing and cautious and slow titration of doses.37
Common opioid-induced side effects are  constipation, 
sedation, nausea, endocrine dysfunction, and altered 
 cognition. These effects should be monitored closely and 
managed promptly, sometimes even preemptively. In addi-
tion to treatment with specific medications, side effects can 
be also managed with dose alteration, change in the route of 
administration, or change to other opioid formulation.
Constipation is the most common side effect of opioids 
and requires prophylaxis in the form of stool softener or 
laxative. Constipation that occurs should be managed aggres-
sively after excluding bowel obstruction. In this setting, it 
may also be necessary to use additional medications for the 
bowel regimen, including lactulose and polyethylene glycol. 
Refractory cases can be managed with peripheral opioid 
antagonist ie, methylnaltrexone.38
Constipation is the most common reason for nausea, so 
its management will be essential for nausea control. There 
are several other antiemetic targets: (a) chemoreceptor trig-
ger zone blockade, managed through droperidol, prochlo-
rperazine, and serotonin antagonism with ondansetron; (b) 
improvement of gastric motility using prokinetic agents, such 
as metoproclamide; and (c) reduction in vestibular sensitivity 
by using antihistaminic and anticholinergics.
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Sedation and altered cognition are usually managed by 
reducing the dosages of opioids, but occasionally stimulants 
such as dextroamphetamine and methylphenidate will be nec-
essary to negate the central nervous system depressive effect 
of opioids. Similarly androgen replacement may be needed 
in opioid-induced hypogonadotropic hypogonadism.39
Opioid rotation is the practice of changing from a poorly 
responsive opiate medication to another in hopes of improved 
analgesia and better tolerability. Although a popular  strategy, 
the practitioner must have a clear understanding of the 
 relative potencies of various opioids for effective opioid 
rotation. These are described in the Opioid Equianalgesic 
Conversion Table (Table 2).
Current guidelines help to ensure patient safety by recom-
mending two key dose adjustments when converting to a new 
opioid: first, calculate the 24-hour requirement of the previous 
opioid and reduce the initial dose of new opioid by 25%–50%, 
using the equianalgesic table. This is done in order to negate 
an “incomplete cross tolerance” among opioids. Second, in 
high-risk patients (elderly, renal-impaired, or cognitively 
impaired), the dose should be further reduced by 15%–30%. 
These guidelines do not apply for methadone, where the initial 
reduction of dose should be 75%–90% to incorporate its vari-
able pharmacokinetics and pharmacodynamics; and fentanyl 
patch doses should not be reduced initially.40
Titration of opioids using 5%–15% increments of the 
total daily dose can be safe when utilizing an appropriate 
frequency of administration and providing medication on 
an “as needed” basis. In time, the patient will achieve the 
desired level of analgesia, and steady state of opioid with 
subsequent administration.40
Upon selection of opioids for chronic use, providers 
should also be mindful of compliance, adherence, depen-
dence, tolerance, and addiction issues. Older adults may have 
difficulty adhering to the plan of care, but educating them 
can help to overcome this problem.
Adjuvants
Adjuvants are pharmacological agents that were primarily 
developed for indications other than analgesia. Several 
medications belong to this group, including antidepres-
sants, antiepileptics, corticosteroids, local anesthetics, 
muscle relaxants, etc. They are commonly used in con-
junction with other analgesics for persistent and refrac-
tory pain, but some adjuvants are drugs of choice for 
neuropathic pain.
Tricyclic antidepressants cause anticholinergic side 
effects, cognitive impairment, and cardiac dysfunction; thus, 
it is recommended to avoid these in the elderly population.29 
Antiepileptics (ie, gabapentin, pregabalin, lamotrigine, 
levetiracetam, tiagabine, and topiramate) are the effective 
agents in treatment of the neuropathic component of pain. 
Titration should be done very slowly as all of these agents 
can produce mild sedation and cognitive alteration. With 
the exception of lamotrigine and tiagabine, all antiepileptic 
dosages should be adjusted on the basis of renal function. 
Gabapentin, pregabalin, and levetiracetam are better choices 
for patients with hepatic dysfunction but adequate renal 
 systems.41 Alternatively tiagabine and lamotrigine may be 
better tolerated by patients with renal impairment.42
Presence of frailty sometimes warrants the use of 
 replacement hormones ie, androgens and/or growth hormones 
for improvement of muscle mass.
Interventional modalities
All practitioners are fully cognizant of the limitations of 
medication and other modalities. In certain situations, an 
interventional approach could be significantly beneficial in 
pain control. These interventions are targeted to the pain path-
ways, to either obliterate or modulate pain signals through 
chemical, electrical, or ablative means.
Analgesia can also be achieved by delivering medications 
peripherally around the nerves or by continuous delivery of 
Table 2 Opioid equianalgesic conversion table
Elimination  
(t½) in hours
IV equivalent to IV morphine  
10 mg (single dose)
PO equivalent to IV morphine 
10 mg (single dose)
Morphine 2–4 10 mg 20–60 mg
Fentanyl 4 100 mcg N/A
Hydrocodone 4 N/A 30–40 mg
Oxymorphone 2–3 1 10
Hydromorphone 3 2 mg 10 mg
Methadone* 20–120 10 mg 10–20 mg
Oxycodone 3 N/A 20–30 mg
Notes: *very long elimination time causes methadone to accumulate over many days.
Abbreviations: Iv, intravenous; PO, oral; N/A, not applicable.
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medication neuraxially via an implantable pump. The pain 
signal can also be affected by neuromodulation, as with use 
of a spinal cord stimulator for pain relief.
Summary
Pain is an extremely common symptom of aging and its man-
agement is a challenging task for any physician, secondary 
to unique individual physiological states, multiple barriers, 
and associated comorbidities.
Despite the presence of significant limitations, effective and 
safe pain management is the patient’s right. Education among 
health professionals, age-targeted clinical trials, frequent and 
detailed pain assessment, utilization of multiple modalities 
concomitantly, and the development of common guidelines 
can facilitate the effective delivery of pain control.
An exponential increase in the number of older adults 
in the total population with chronic degenerative patholo-
gies presents a significant burden on the current health 
care system. More elderly-focused, age-specific, clinical, 
socioeconomic, and epidemiological studies are needed to 
promote healthy aging, as well as early, safe, and effective 
management of health problems, including pain.
In summary we recommend the following steps in pain 
management for frail older adults (Figure 1):29
•	 Provide a rational, individualized plan of care
•	 Provide comprehensive pain assessment, as this is 
 essential in developing an individualized management 
plan
•	 Use physical therapy and occupational therapy to keep 
older patients active and mobile
Pharmacology
1. Review pain type, comorbid status, medicinal history 
2. Understand physiological changes associated with aging 
3. Avoid high-risk medications per “Beer’s Criteria” ie, tricyclic antidepressants,  
NSAIDs, etc 
4. Choose and adjust dosage according to patient’s hepatic and renal functional status 
5. Choose least invasive route of delivery of medicine ie, oral, topical, etc
6. Start with lowest effective dose 
7. Titrate slow – 
Give enough intervals between dose changes to determine its effects  
For opioids, use the analgesic ladder, increase dose by 30%–50% in 24 or more 
hours 
8. Frequent and close monitoring for therapeutic efficacy and possible adverse 
events, especially upon each change in dosage  
9. Side effects – recognize early and treat early  
Management
Education of patient and health care providers, to overcome their misplaced beliefs and biases 
and keep them up to date with new developments 
Clear and frequent communication between patient, family, and health care providers 
Formulation of individualized, multimodal care plans incorporating pharmacological, injections  
or surgical intervention, psychological, physical therapy, social and spiritual interventions 
simultaneously
Diagnosis 
Hierarchy Pain Assessment tool – cognitive intact vs cognitive impairment  
Diagnostic tests 
Assessment
Detailed history –  pain, comorbidities, medicinal, impact of pain 
Detailed physical examination – pain, comorbidities  
Mental status, function, and frailty 
 
 
Figure 1 Management of pain in frail older adults.
Abbreviation: NSAID, nonsteroidal anti inflammatory drug.
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•	 Avoid high-risk medication (ie, tricyclic antidepressants, 
nonsteroidal anti-inflammatory drugs, etc), as recom-
mended by the BEERS criteria20
•	 Avoid polypharmacy, if possible
•	 Use the least invasive drug-delivery route
•	 Use the lowest effective dose by starting at low dose and 
titrating slowly to the desired level
•	 Allow for adequate time to evaluate the dose response
•	 Adjust doses in patients with renal/hepatic impairment 
or other comorbidities
•	 Adjust one medication at a time
•	 Use multimodality treatment to get the most effective 
results with least side effects
•	 Reevaluate after each change in plan, and monitor side 
effects, drug–drug interactions, and drug efficacy.
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